Should You Buy Sarepta Stock At $71?
- Thursday, April 22, 2021, 7:10
- Market
- Add a comment
We believe that the stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is undervalued at current levels of $71. SRPT stock is down 20% off the March 2020 bottom compared…
About the Author
admin123 has written 23546 stories on this site.
